Harbor Capital Advisors, Inc. Catalyst Pharmaceuticals, Inc. Transaction History
Harbor Capital Advisors, Inc.
- $2.19 Billion
- Q1 2025
A detailed history of Harbor Capital Advisors, Inc. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Harbor Capital Advisors, Inc. holds 231 shares of CPRX stock, worth $5,266. This represents 0.0% of its overall portfolio holdings.
Number of Shares
231Holding current value
$5,266% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CPRX
# of Institutions
351Shares Held
98.6MCall Options Held
13.4KPut Options Held
11.7K-
Black Rock Inc. New York, NY18.7MShares$426 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$192 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$132 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.13MShares$71.4 Million1.62% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.01MShares$68.7 Million0.02% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.34B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...